No article text was recorded for this version.
adoptive cellular immunotherapy
Version 1 of 128 papers40 conceptsfrozen 2026-10-04
Papers in this version
- Blog: Personalized Chimeric Antigen Receptor T- Cell Immunotherapy for Patients with Recurrent Malignant Gliomas
- Blog: Adoptive cell therapy for cancer treatment
- Blog: Anti-tumor efficacy of anti-GD2 CAR NK-92 cells in diffuse intrinsic pontine gliomas
- Blog: Frontiers and future of immunotherapy for pancreatic cancer: from molecular mechanisms to clinical application
- Blog: Identification of glioblastoma-specific antigens expressed in patient-derived tumor cells as candidate targets for chimeric antigen receptor T cell therapy
- Blog: The Chemokine Receptor CCR8 Is a Target of Chimeric Antigen T Cells for Treating T Cell Malignancies
- Blog: GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas
- Blog: CD70: An emerging target for integrated cancer diagnosis and therapy
- Blog: TIL-Derived CAR T Cells Improve Immune Cell Infiltration and Survival in the Treatment of CD19-Humanized Mouse Colorectal Cancer
- Blog: mRNA Vaccines: Current Applications and Future Directions
- Blog: Next-generation immunotherapy biologics for glioblastoma
- Blog: Cytokines induced memory-like NK cells engineered to express CD19 CAR exhibit enhanced responses against B cell malignancies
- Blog: Immunotherapy for Glioblastoma: Current State, Challenges, and Future Perspectives
- Blog: Natural killer cell-specific chimeric antigen receptor enhances CAR NK cell functions and anti-tumor activity
- Blog: Perspectives on Immunotherapy of Metastatic Colorectal Cancer
- Blog: Naturally selected CD7 CAR-T therapy without genetic editing demonstrates significant antitumour efficacy against relapsed and refractory acute myeloid leukaemia (R/R-AML)
- Blog: Prospects of Immunotherapy for Triple-Negative Breast Cancer
- Blog: mRNA vaccines in tumor targeted therapy: mechanism, clinical application, and development trends
- Blog: mRNA Vaccines: a Powerful Tool in Cancer Treatment
- Blog: Evaluation of B7-H3 Targeted Immunotherapy in a 3D Organoid Model of Craniopharyngioma
- Blog: CD37 is a safe chimeric antigen receptor target to treat acute myeloid leukemia
- Blog: B7-H3, a checkpoint molecule, as a target for cancer immunotherapy
- Blog: Absence of central tolerance in Aire-deficient mice synergizes with immune-checkpoint inhibition to enhance antitumor responses
- Blog: Immunotherapy and Radioimmunotherapy for Desmoplastic Small Round Cell Tumor
- Blog: The next bastion to be conquered in immunotherapy: microsatellite stable colorectal cancer
- Blog: First-in-Human Trial of EphA2-Redirected CAR T-Cells in Patients With Recurrent Glioblastoma: A Preliminary Report of Three Cases at the Starting Dose
- Blog: The Development of Immunotherapy for the Treatment of Recurrent Glioblastoma
- Blog: TCR engineered T cells for solid tumor immunotherapy
History & citation
Current · Permanent link
Cite this direction
Latest version (a living page):
@misc{lacuna_adoptive_cellular_immunotherapy_8dbab90c,
title = {adoptive cellular immunotherapy},
author = {{Lacuna}},
howpublished = {Lacuna research direction},
year = {2026},
url = {https://lacuna.tiptreesystems.com/direction/adoptive-cellular-immunotherapy/rdr_8dbab90c83884691863b9f30e4b56430},
note = {Latest version of a living research direction; cite a version for a fixed text. Accessed 2026-11-21},
}This exact version (version 1, frozen text):
@misc{lacuna_adoptive_cellular_immunotherapy_8dbab90c_v1,
title = {adoptive cellular immunotherapy},
author = {{Lacuna}},
howpublished = {Lacuna research direction},
year = {2026},
url = {https://lacuna.tiptreesystems.com/direction/adoptive-cellular-immunotherapy/rdr_8dbab90c83884691863b9f30e4b56430/v/1},
note = {Version 1, frozen 2026-10-04. Accessed 2026-11-21},
}